Physician profile
Jack A Chapman
NPI 1710975701
$23,787.36
in general payments reported to CMS, 2019-2025
22 companies · $7,813 in 2025
The $7,813 reported for 2025 was more than what 93% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,191 · 2020: $724 · 2021: $1,588 · 2022: $3,163 · 2023: $4,064 · 2024: $4,245 · 2025: $7,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,387 · Consulting Fee: $5,500 · Travel and Lodging: $2,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,387.11 |
| Consulting Fee | $5,500.00 |
| Travel and Lodging | $2,234.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,176.82 | 2019-2025 | Proclaim, Octrode, Eterna |
| Si-Bone, INC. | $6,376.65 | 2024-2025 | |
| Medtronic, INC. | $2,631.35 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Vanta Adaptivestim |
| Painteq LLC | $2,194.10 | 2021-2024 | Painteq |
| Boston Scientific Corporation | $1,272.16 | 2020-2025 | Intracept, Intracept Rf Probe |
| Medtronic USA, INC. | $1,095.95 | 2019-2020 | |
| Spr Therapeutics, INC | $709.89 | 2023-2025 | Sprint Pns System |
| Mml US, INC. | $475.11 | 2025 | Reactiv8 |
| Nevro Corp. | $332.41 | 2021-2023 | Senza |
| Relievant Medsystems, INC. | $297.88 | 2022-2023 | Intracept |
| Stryker Corporation | $270.58 | 2021 | |
| Glaukos Corporation | $238.64 | 2025 | Idosetr |
| Globus Medical, INC. | $178.75 | 2025 | Senza, Omnia |
| Saluda Medical Americas, INC. | $153.17 | 2023-2024 | Evoke Scs, Evoke |
| Flowonix Medical Incorporated | $110.48 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $85.52 | 2023-2025 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.02 | 2024 | Relistor |
| Collegium Pharmaceutical, INC. | $32.69 | 2023-2024 | Xtampza |
| Eagle Pharmaceuticals, INC. | $24.05 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $19.32 | 2025 | Zilretta, Iovera |
| Ibsa Pharma INC. | $18.79 | 2024 | Tirosint, Licart, Flector |
| Vertos Medical, INC. | $14.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.